1.98 USD
+0.05 (+2.59%)
Taking everything into account, VIVS scores 4 out of 10 in our fundamental rating. VIVS was compared to 531 industry peers in the Biotechnology industry. While VIVS seems to be doing ok healthwise, there are quite some concerns on its profitability. VIVS has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
VIVS had positive earnings in the past year.
VIVS had a negative operating cash flow in the past year.
VIVS had negative earnings in each of the past 5 years.
In the past 5 years VIVS always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -20.47%, VIVS is in the better half of the industry, outperforming 75.75% of the companies in the same industry.
With a decent Return On Equity value of -28.07%, VIVS is doing good in the industry, outperforming 78.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.47% | ||
| ROE | -28.07% | ||
| ROIC | N/A |
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 98.57%, VIVS belongs to the best of the industry, outperforming 97.93% of the companies in the same industry.
VIVS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for VIVS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.57% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
2. Health
2.1 Basic Checks
VIVS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VIVS has been reduced compared to 1 year ago.
Compared to 5 years ago, VIVS has less shares outstanding
VIVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -52.55, we must say that VIVS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -52.55, VIVS is not doing good in the industry: 93.23% of the companies in the same industry are doing better.
There is no outstanding debt for VIVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -52.55 |
ROIC/WACCN/A
WACC8.8%
2.3 Liquidity
A Current Ratio of 3.10 indicates that VIVS has no problem at all paying its short term obligations.
VIVS has a worse Current ratio (3.10) than 63.53% of its industry peers.
VIVS has a Quick Ratio of 3.10. This indicates that VIVS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.10, VIVS is doing worse than 61.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.1 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 278.71% over the past year.
VIVS shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.92%.
Measured over the past years, VIVS shows a very negative growth in Revenue. The Revenue has been decreasing by -42.03% on average per year.
EPS 1Y (TTM)278.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-589.48%
Revenue 1Y (TTM)35.92%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%-6.67%
3.2 Future
Based on estimates for the next years, VIVS will show a decrease in Earnings Per Share. The EPS will decrease by -6.30% on average per year.
The Revenue is expected to grow by 16.82% on average over the next years. This is quite good.
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 1.04 indicates a rather cheap valuation of VIVS.
VIVS's Price/Earnings ratio is rather cheap when compared to the industry. VIVS is cheaper than 99.81% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.38. VIVS is valued rather cheaply when compared to this.
VIVS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.04 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as VIVS's earnings are expected to decrease with -6.30% in the coming years.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y-6.3%
EPS Next 3YN/A
5. Dividend
5.1 Amount
VIVS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:VIVS (12/19/2025, 8:20:36 PM)
1.98
+0.05 (+2.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners7.38%
Inst Owner ChangeN/A
Ins Owners0.6%
Ins Owner ChangeN/A
Market Cap5.17M
Revenue(TTM)140.00K
Net Income(TTM)-1.98M
Analysts45.71
Price TargetN/A
Short Float %1.49%
Short Ratio0.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-33.96%
Min Revenue beat(2)-45.1%
Max Revenue beat(2)-22.82%
Revenue beat(4)1
Avg Revenue beat(4)-26.44%
Min Revenue beat(4)-46.52%
Max Revenue beat(4)8.7%
Revenue beat(8)2
Avg Revenue beat(8)-32.76%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.04 | ||
| Fwd PE | N/A | ||
| P/S | 36.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.73 | ||
| P/tB | 0.73 | ||
| EV/EBITDA | N/A |
EPS(TTM)1.91
EY96.46%
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-3.89
FCFYN/A
OCF(TTM)-3.89
OCFYN/A
SpS0.05
BVpS2.71
TBVpS2.71
PEG (NY)0.4
PEG (5Y)N/A
Graham Number10.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.47% | ||
| ROE | -28.07% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.57% | ||
| FCFM | N/A |
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
F-Score4
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.1 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | -52.55 |
F-Score4
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)52.61%
Cap/Depr(5y)295.14%
Cap/Sales(3y)51.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)278.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-589.48%
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)35.92%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%-6.67%
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.48%
OCF growth 3YN/A
OCF growth 5YN/A
VIVOSIM LABS INC / VIVS FAQ
What is the ChartMill fundamental rating of VIVOSIM LABS INC (VIVS) stock?
ChartMill assigns a fundamental rating of 4 / 10 to VIVS.
What is the valuation status for VIVS stock?
ChartMill assigns a valuation rating of 4 / 10 to VIVOSIM LABS INC (VIVS). This can be considered as Fairly Valued.
What is the profitability of VIVS stock?
VIVOSIM LABS INC (VIVS) has a profitability rating of 3 / 10.
Can you provide the financial health for VIVS stock?
The financial health rating of VIVOSIM LABS INC (VIVS) is 6 / 10.